ResponseUsing qualitative data, people's perceptions, and the science of decision making to inform policy and improve hepatitis C care for people who use drugs
Section snippets
Conflicts of interest and grant support
The authors have no conflicts of interest to disclose. This work was supported by National Institute on Drug Abuse P30 DA011041.
References (25)
- et al.
Global estimates of prevalence of HCV infection among injecting drug users
International Journal of Drug Policy
(2007) - et al.
Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: Systematic review of qualitative research
International Journal of Drug Policy
(2014) - et al.
Use of research to inform public policymaking
Lancet
(2004) - et al.
Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.
International Journal of Drug Policy
(2008) - et al.
Perceptions of genetic testing and genomic medicine among drug users
International Journal of Drug Policy
(2015) - et al.
Non-injection drug use and hepatitis C virus: A systematic review
Drug and Alcohol Dependence
(2007) The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States
Clinics in Liver Disease
(2013)- et al.
Shared decision making—The pinnacle of patient-centered care
New England Journal of Medicine
(2012) - et al.
Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity
The Journal of Infectious Diseases
(2011) - et al.
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place
American Journal of Epidemiology
(2008)
Evaluation of the quality of prognosis studies in systematic reviews
Annals of Internal Medicine
Cited by (4)
An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential
2015, International Journal of Drug PolicyCitation Excerpt :Point of care HCV tests have the potential to allow widespread testing in OST settings where medical infrastructure is limited. Currently these tests are not routinely conducted or funded at OST programs, and since positive point of care tests require subsequent viral load testing and linkage to care, gaps in the HCV care are often introduced at these steps (Morano et al., 2014; Perlman & Jordan, 2015). Regardless of whether HCV testing is done on site or off site by effective linkage, its potential contribute to HCV control (through primary prevention and through enhancing TasP) would be enhanced by strategies to address identified barriers to, and to utilize identified facilitators of, HCV testing among PWID (Harris & Rhodes, 2013; Jordan et al., 2013; Lally, Montstream-Quas, Tanaka, Tedeschi, & Morrow, 2008).
“If I Get Cured, My Whole Quality of Life Will Change”: Patients’ Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C
2022, Digestive Diseases and Sciences